RxDoctor Payments Data

Sergey Rybalov, MD

Gastroenterology · Dover, NJNPI 1386670552

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $300 of the $454 with a category attached, or 66.0%. BD accounts for 66.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $300 and has fallen 82.6% since, to $52 in 2025. That places this record below the midpoint for gastroenterology clinicians in NJ, where the typical reported total is $2,298.

$454in general payments, 2019–2025

Across 11 payments — averaging $41.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BD$300
  • Gilead$100
  • Intercept Pharmaceuticals, Inc.$15
  • Novo Nordisk$14
  • Ferring Pharmaceuticals Inc.$14
  • AbbVie$12

What the payments were for

  • Consulting fees$30066%
  • Food & beverage$15434%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$454 in reported general payments places this provider in the 20th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$131,251
Medicare patients
442
Services billed
1,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase27$132,943
LinzessLinaclotide39$34,830
Mesalamine51$24,397
Pantoprazole Sodium432$6,059
Sucralfate12$5,339
ClenpiqSod Picosulf/Mag Ox/Citric Ac29$5,059
CholestyramineCholestyramine (With Sugar)28$2,221
Dicyclomine Hcl63$1,560
Budesonide DrBudesonide12$1,502
Omeprazole106$1,406
Famotidine53$723
Esomeprazole Magnesium33$648
Lansoprazole19$610
Ondansetron OdtOndansetron25$525
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine16$484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$12$167,77266 claims
Ferring Pharmaceuticals Inc.Clenpiq$14$5,05929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Dover

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →